Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
TXMD
$1.75
-3.85%
TXMD
· TherapeuticsMD, Inc.
$1.75
-0.07 (-3.85%)
At close · Nov 5
View the 10-Q filed Aug 11, 2026
Return incl. dividend (before tax)
Q2 2022 earnings call transcript
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$21.07M
Shares
11.57M
Volume · Nov 5
3554
Avg daily vol (3M)
23.41K
All webcasts
Earnings call · FY2022 Q3
TherapeuticsMD, Inc. (TXMD) Q3 2022 Earnings Call
Revenue
$354,000
-98.6% YoY
Diluted EPS
-$3.13
Gross margin
0.0%
-79.2 pp YoY
Net income
-$28.96M
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Nov 14, 2022 · complete as-filed document
SEC periodic report
10-Q report
Filed Nov 14, 2022 · complete as-filed document